Gary Eichenbaum
Janssen Pharmaceutica
6 Papers
46 Citations
Gary Eichenbaum is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Tapentadol & Opioid. The author has an hindex of 3, co-authored 6 publications. Previous affiliations of Gary Eichenbaum include Service New Brunswick.
Chat about Author
Papers
Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency.
Gary Eichenbaum,Karin Göhler,Mila Etropolski,Ilona Steigerwald,Joseph V. Pergolizzi,Myoung Kim,G. Vorsanger +6 more
TL;DR: The results suggest that tapentadol, which has combined MOR and NRI activities, may have a lower impact on sex hormone concentrations than pure opioid analgesics, such as morphine or oxycodone.
37
Case Study 5. Deconvoluting Hyperbilirubinemia: Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A1, MRP2, or OATP1B1 in Drug Development
TL;DR: This chapter aims to demonstrate application of enzyme kinetic principles in understanding the risk of bilirubin elevation through inhibition of multiple processes-involving both enzymes and transporters.
11
The thrombopoietin mimetic JNJ-26366821 increases megakaryopoiesis without affecting malignant myeloid proliferation
Diego Adrianzen-Herrera,Gaurav Choudhary,Shanisha Gordon-Mitchell,Nandini Ramachandra,Tushar D. Bhagat,Hui Zhang,Srinivas Aluri,Aditi Shastri,Ulrich Steidl,Britta Will,Weng Lang Yang,Michelle Mahler,Gary Eichenbaum,Chandan Guha,Amit Verma +14 more
TL;DR: The results show that JNJ-26366821 stimulates megakaryopoiesis without causing proliferation of the malignant myeloid clones in MDS/AML and provides the rationale for clinical testing of JNJ's TPO mimetic in myeloids malignancies.
2
Patent
Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
Gary Eichenbaum
- 19 Jun 2007
TL;DR: In this paper, a method for enhancing the activity of a therapeutic agent comprising the administration of the agent in combination with an enzyme, whereby a metabolic pathway of the therapeutic agent is counteracted and the agent's pharmacokinetics and metabolism are modulated.
emptying: potential role of vagal inhibition Pramlintide, an amylin analog, selectively delays gastric
Lawrence A. Szarka,Adrian Vella,R Alan,Bianca Feyen,J. Vandenberghe,Anton Megens,Elaine Knight,Kelley Michael F,Siegrid Damsch,Gary Eichenbaum,Alfred Tonelli,Lieve Lammens,Kathleen Van den Bulck +12 more
- 01 Jan 2011